Trial Profile

A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fipaxalparant (Primary)
Indications Diffuse scleroderma
Focus Adverse reactions; Therapeutic Use
Acronyms Diffuse Cutaneous SSc
Sponsors Amgen

Most Recent Events

10 Mar 2025 According to ClinicalTrials.gov, this trial is terminated due to the parent trial (HZNP-HZN-825-301) meeting pre-defined criteria for futility
10 Mar 2025 Status changed from recruiting to discontinued.
05 Feb 2025 Planned End Date changed from 25 Sep 2026 to 24 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com